Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leif Mosekilde

Showing results (41-50 of 159) with videos related to

Pageof 16
Sort By:
Current Drug Safety|April 29, 2011
Vitamin D treatment in primary hyperparathyroidismLars Rolighed, Jens Bollerslev, Leif Mosekilde
Ugeskrift for Laeger|July 16, 2002
[Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects]Thor Ueland, Jens Bollerslev, Leif Mosekilde
Current Drug Safety|April 29, 2011
Emerging anabolic treatments in osteoporosisLeif Mosekilde, Ove Tørring, Lars Rejnmark
Chest|September 25, 2007
Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroidsPeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Calcified Tissue International|December 17, 2010
Are antiresorptive drugs effective against fractures in patients with diabetes?Peter Vestergaard, Lars Rejnmark, Leif Mosekilde
Archives of Dermatology|May 19, 2010
High-dose treatment with vitamin A analogues and risk of fracturesPeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Calcified Tissue International|January 5, 2008
Anxiolytics and sedatives and risk of fractures: effects of half-lifePeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Calcified Tissue International|May 9, 2008
Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancerPeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Calcified Tissue International|December 11, 2008
Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetesPeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Current Drug Safety|April 29, 2011
PTH treatment in hypoparathyroidismTanja Sikjaer, Lars Rejnmark, Leif Mosekilde
Pageof 16

Showing results (41-50 of 159) with videos related to

Sort By:
Pageof 16
Current Drug Safety|April 29, 2011
Vitamin D treatment in primary hyperparathyroidismLars Rolighed, Jens Bollerslev, Leif Mosekilde
Ugeskrift for Laeger|July 16, 2002
[Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects]Thor Ueland, Jens Bollerslev, Leif Mosekilde
Current Drug Safety|April 29, 2011
Emerging anabolic treatments in osteoporosisLeif Mosekilde, Ove Tørring, Lars Rejnmark
Chest|September 25, 2007
Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroidsPeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Calcified Tissue International|December 17, 2010
Are antiresorptive drugs effective against fractures in patients with diabetes?Peter Vestergaard, Lars Rejnmark, Leif Mosekilde
Archives of Dermatology|May 19, 2010
High-dose treatment with vitamin A analogues and risk of fracturesPeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Calcified Tissue International|January 5, 2008
Anxiolytics and sedatives and risk of fractures: effects of half-lifePeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Calcified Tissue International|May 9, 2008
Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancerPeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Calcified Tissue International|December 11, 2008
Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetesPeter Vestergaard, Lars Rejnmark, Leif Mosekilde
Current Drug Safety|April 29, 2011
PTH treatment in hypoparathyroidismTanja Sikjaer, Lars Rejnmark, Leif Mosekilde
Pageof 16